Orphazyme may face class action suit from US investors
A potential lawsuit in the US may be on the cards for Copenhagen-based biotech company Orphazyme, according to the company's H1 report. This is happening after several disappointments for the company over the past half-year, though the CEO and CFO say the suit is unfounded.
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
Copehagen-based biotech company Orphazyme may be facing legal proceedings in the US, as lawyers are hunting for investors to join a possible class action suit.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme expects to lay off 100 employees this year
For subscribers
Orphazyme postpones financial report
For subscribers
